Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Arch Therapeutics, Inc. (ARTH)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0200-0.0035 (-14.89%)
At close: 03:51PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0235
Open0.0206
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0180 - 0.0234
52 Week Range0.0101 - 0.1400
Volume914,826
Avg. Volume442,680
Market Cap4.998M
Beta (5Y Monthly)-0.04
PE Ratio (TTM)N/A
EPS (TTM)-0.0240
Earnings DateDec 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ARTH

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ARCH THERAPEUTICS INC
    Analyst Report: Becton, Dickinson And Co.Headquartered in Franklin Lakes, New Jersey, BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, industry, and the general public. Its operations consist of three worldwide business segments: BD Medical, BD Life Sciences, and BD Interventional.
    Rating
    Fair Value
    Economic Moat
    7 days agoArgus Research
View more
  • GlobeNewswire

    Arch Therapeutics Announces First Shipments of AC5® Advanced Wound System Under New Reimbursement Support Program

    Significant Milestone in Commercialization Plan Expected to Drive Sales MomentumFRAMINGHAM, Mass., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today confirmed the first shipments of AC5® Advanced Wound System (“AC5”) under the Company’s new reimbursement support program (the “Program”). This development represents a significant milestone in the Company’s

  • GlobeNewswire

    Arch Therapeutics Accepted to Present AC5® Advanced Wound System During Innovation Spotlight at 2022 Symposium on Advanced Wound Care (SAWC)

    Prestigious Honor Supports Increasing Interest in Broad Clinical Benefits of Synthetic Products in Wound HealingFRAMINGHAM, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that AC5® Advanced Wound System (“AC5”) was selected for the “Innovation Spotlight: Shining a Light on Bold Ideas in Wound Care” session at the 2022 Symposium on Adva

  • GlobeNewswire

    Arch Therapeutics Announces Intent to Uplist from OTC to a National Exchange

    Consistent with Long-Term Strategic Plan to Increase Capital Market Visibility and Enhance Access to Growth CapitalFRAMINGHAM, Mass., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided an update regarding its intent to list its common stock on a national exchange (the “Uplisting”) by the end of 2022 or early 2023. Management believes the Uplisting

Advertisement
Advertisement